The proteolysis targeting chimera GMB-475 combined with dasatinib for the treatment of chronic myeloid leukemia with BCR::ABL1 mutants.

Ye, Wu; Wu, Xia; Wang, Xiaojia; Wei, Xiaoyu; Tang, Yuqian; Ouyang, Xianfeng; Gong, Yuping

Ye, Wu; Wu, Xia; Wang, Xiaojia; Wei, Xiaoyu; Tang, Yuqian; Ouyang, Xianfeng; Gong, Yuping.

Afiliação

Ye W; Department of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Wu X; Department of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Wang X; Department of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Wei X; Department of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Tang Y; Department of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Ouyang X; Department of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Gong Y; Department of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

Front Pharmacol ; 13: 931772, 2022.

Article em En | MEDLINE | ID: mdl-36263131

Palavras-chave

BCR::ABL1 mutants; GMB-475; chronic myeloid leukemia; combination therapy; dasatinib

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Front Pharmacol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google